Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma.

The oncologist - 1 Oct 2021

Babacan Nalan Akgul, Peguero Edwin, Forsyth Peter, Eroglu Zeynep

Abstract excerpt

INTRODUCTION: BRAF inhibitors such as encorafenib and vemurafenib in combination with MEK inhibitors are commonly used for the treatment of patients with BRAF V600-mutant melanoma. CASE PRESENTATION: A patient with relapsed metastatic melanoma with a BRAF V600 mutation was started on treatment with vemurafenib and cobimetinib. Within 2 weeks of treatment start, he was hospitalized and diagnosed with encephalitis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Encephalitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34227206
DOI: 10.1002/onco.13896
PMCID: PMC8488772

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma.PMID 34227206Read ↗

Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.Semantic proximity Read ↗

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.Semantic proximity Read ↗

Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report.Semantic proximity Read ↗

Melanoma brain metastases and vemurafenib: need for further investigation.Semantic proximity Read ↗

Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study.Semantic proximity Read ↗

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.Semantic proximity Read ↗

BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.Semantic proximity Read ↗

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Semantic proximity Read ↗

Atezolizumab- and bevacizumab -induced encephalitis in a patient with advanced hepatocellular carcinoma: a case report and literature reviewSemantic proximity Read ↗

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy.Semantic proximity Read ↗

Successful rechallenge therapy for BRAF/MEK inhibitor-resistant multiple brain metastases of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.